The fact that Lipedema almost exclusively affects women, and that it tends to emerge or worsen at predictable hormonal turning points in a woman’s life, tells us something important about its biology. This is not a coincidence. The hormonal pattern is one of the most consistent observations in the clinical literature, and it is one of the reasons oestrogen has become a central focus of Lipedema research.

At puberty, oestrogen levels rise rapidly. This is the point at which many women first notice that their legs are developing differently: disproportionately, painfully, in a way that does not match the rest of their body’s changes. During pregnancy, another period of significant hormonal activity, some women experience a first onset and others a marked worsening. After delivery, some find symptoms improve slightly, only to worsen again with subsequent pregnancies or later hormonal changes.

Perimenopause and menopause represent a particularly significant turning point for many women with Lipedema. The hormonal fluctuations of this period, especially the eventual decline in oestrogen production, appear to destabilise the condition. Some women describe rapid progression during this phase, with tissue changes that had been relatively stable suddenly accelerating. A 2025 paper proposed a specific model for this: an imbalance in oestrogen receptors in adipose tissue, combined with the local production of oestrogen within the fat itself, may be what drives the dysfunction rather than oestrogen levels in the blood alone.

PCOS is associated with Lipedema more often than chance would predict. The hormonal dysregulation in PCOS, which affects oestrogen activity alongside elevated androgens and often insulin resistance, may interact with the same pathways involved in Lipedema fat behaviour. If you have both conditions, it is worth making sure that any clinician assessing you is aware of the full picture.

It is important to be precise about what hormones do and do not do in this context. Hormonal changes do not cause Lipedema in women who do not have the underlying predisposition. They appear to act as triggers that bring out or worsen a condition that is already there at a genetic and cellular level. This distinction matters because it is sometimes suggested that hormonal interventions could treat or prevent Lipedema. The evidence for that is not there yet, and hormonal management should only ever be explored in a specialist context for conditions other than Lipedema itself.